Enhancing breast milk production with Domperidone in mothers of preterm neonates (EMPOWER trial)

Elizabeth V Asztalos, Marsha Campbell-Yeo, Orlando P daSilva, Alex Kiss, David C Knoppert, Shinya Ito, Elizabeth V Asztalos, Marsha Campbell-Yeo, Orlando P daSilva, Alex Kiss, David C Knoppert, Shinya Ito

Abstract

Background: The use of mother's own breast milk during initial hospitalization has a positive impact not only in reducing potential serious neonatal morbidities but also contribute to improvements in neurodevelopmental outcomes. Mothers of very preterm infants struggle to maintain a supply of breast milk during their infants' prolonged hospitalization. Galactogogues are medications that induce lactation by exerting its effects through oxytocin or prolactin enhancement. Domperidone is a potent dopamine D2 receptor antagonist which stimulates the release of prolactin. Small trials have established its ability in enhancing breast milk production. EMPOWER was designed to determine the safety and efficacy of domperidone in mothers experiencing an inadequate milk supply.

Methods/design: EMPOWER is a multicenter, double masked, randomized controlled phase-II trial to evaluate the safety and effectiveness of domperidone in those mothers identified as having difficulty in breast milk production. Eligible mothers will be randomized to one of two allocated groups: Group A: domperidone 10 mg orally three times daily for 28 days; and Group B: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days. The primary outcome will be determined at the completion of the first 2-week period; the second 2-week period will facilitate answering the secondary questions regarding timing and duration of treatment. To detect an estimated 30% change between the two groups (from 40% to 28%, corresponding to an odds ratio of 0.6), a total sample size of 488 mothers would be required at 80% power and alpha=0.05. To account for a 15% dropout, this number is increased to 560 (280 per group). The duration of the trial is expected to be 36-40 months.

Discussion: The use of a galactogogue often becomes the measure of choice for mothers in the presence of insufficient breast milk production, particularly when the other techniques are unsuccessful. EMPOWER is designed to provide valuable information in guiding the practices for this high-risk group of infants and mothers. The results of this trial will also inform both mothers and clinicians about the choices available to increase and maintain sufficient breast milk.

Trial registration: Clinical Trials.gov Identifier: NCT01512225.

Figures

Figure 1
Figure 1
EMPOWER Schema.

References

    1. Health Canada. Canadian Perinatal Health Report 2003. Ottawa: Ministry of Public Works and Government Services Canada. 2003.
    1. Statistics Canada. Births and birth rate, by province and territory. 2011. Available at: . Last modified: 2011-12-20.
    1. O'Connor DL, Jacobs J, Hall R. et al.Growth and development of premature infants fed predominantly human milk, predominantly premature infant formula, or a combination of human milk and premature formula. J Pediatr Gastroenterol Nutr. 2003;37:437–446. doi: 10.1097/00005176-200310000-00008.
    1. Morley R, Lucas A. Influence of early diet on outcome of preterm infants. Acta Paediatr Suppl. 1994;405:123–126.
    1. Morley R. The influence of early diet on later development. J Biosoc Sci. 1996;28(4):481–487.
    1. Lucas A, Morley R, Cole TJ. Randomised trial of early diet in preterm babies and later intelligence quotients. BMJ. 1996;317:1481–1487.
    1. Vohr BR, Poindexter BB, Dusick AM. et al.Persistent beneficial effects of breast milk ingested in the neonatal intensive care unit on outcomes of extremely low birth weight infants at 30 months of age. Pediatrics. 2007;120:e953–e959. doi: 10.1542/peds.2006-3227.
    1. Horwood LJ, Darlow BA, Mogridge N. Breast milk feeding and cognitive ability at 7–8 years. Arch Dis Child Fetal Neonatal Ed. 2001;84:F23–F27. doi: 10.1136/fn.84.1.F23.
    1. Vohr BR, Poindexter BB, Dusick AM. et al.Beneficial effects of breast milk in the neonatal intensive care unit on the developmental outcome of extremely low birth weight infants at 18 months of age. Pediatrics. 2006;118:e115–e123. doi: 10.1542/peds.2005-2382.
    1. Anderson JW, Johnstone BM, Remley DT. Breast-feeding and cognitive development: a metaanalysis. Am J Clin Nutr. 1999;70(4):525–535.
    1. Horwood LJ, Fergusson DM. Breastfeeding and later cognitive and academic outcomes. Pediatrics. 1998;101(1):E9. doi: 10.1542/peds.101.1.e9.
    1. Horwood LJ, Mogridge N, Darlow BA. Cognitive, educational, and behavioural outcomes at 7 to 8 years in a national very low birthweight cohort. Arch Dis Child Fetal Neonatal Ed. 1998;79(1):F12–F20. doi: 10.1136/fn.79.1.F12.
    1. Callen J, Pinelli J. A review of the literature examining the benefits and challenges, incidence and duration, and barriers to breastfeeding in preterm infants. Adv Neonatal Care. 2005;5(2):72–88. doi: 10.1016/j.adnc.2004.12.003.
    1. Hill PD, Ledbetter RJ, Kavanaugh KL. Breastfeeding patterns of low-birth-weight infants after hospital discharge. JOGNN: J Obstet Gynecol Neonatal Nurs. 1997;26:189–197. doi: 10.1111/j.1552-6909.1997.tb02132.x.
    1. Hill PD, Aldag JC, Chatterton RT, Zinaman MJ. Comparison of milk production between mothers of preterm and term mothers: the first six weeks after birth. J Hum Lact. 2005;21:22–30. doi: 10.1177/0890334404272407.
    1. Lefebvre F, Ducharme M. Incidence and duration of lactational performance among mothers of low-birth-weight and term infants. CMAJ. 1989;140:1159–1164.
    1. Gabay PG. Galactogogues: medications that induce lactation. J Hum Lact. 2002;18:274–279.
    1. De Leo V, Petraglia F, Sardelli S. et al.Use of domperidone in the induction and maintenance of maternal breast feeding. Minerva Ginecol. 1986;38:311–315.
    1. Petraglia F, De Leo V, Sardelli S, Pieroni ML, D’Antona N, Genazzani AR. Domperidone in defective and insufficient lactation. Eur J Obstet Gynecol Reprod Biol. 1985;19:281–287. doi: 10.1016/0028-2243(85)90042-5.
    1. da Silva OP, Knoppert DC, Angelini MM, Forret PA. Effect of domperidone on milk production in mothers of premature newborn: a randomized, double-blind, placebo-controlled trial. CMAJ. 2001;164:17–21.
    1. Campbell-Yeo M, Allen AC, Joseph KS, Ledwidge J, Allen V, Dooley K. Effect of Domperidone on the Composition of Preterm Human Breast Milk: Randomized, Double Blind, Placebo-Controlled Trial. Pediatrics. 2010;125:e107–e114. doi: 10.1542/peds.2008-3441.
    1. Ingram J, Taylor H, Churchill Pike A, Greenwood R. Metoclopramide or domperidone for increasing maternal breast milk output: a randomized controlled trial. Arch Dis Child Fetal Neonatal Ed. 2012;97:F241–F245. doi: 10.1136/archdischild-2011-300601.
    1. Knoppert DC, Page A, Warren J, Seabrook JA, Carr M, Angelini M, Killick D, DaSilva OP. The effect of two different domperidone doses on maternal milk production. J Hum Lact. 2012; : . doi: 10.1177/0890334412438961.
    1. Meier PP, Brown LP, Hurst N. Breastfeeding and Human Lactation. Boston: Jones & Bartlett; 1999. Breastfeeding the preterm infant; pp. 449–481.
    1. Good Clinical Practice. Consolidated Guideline. Ottawa: Minister of Health; 2012. .

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅